Instead, apoB or non-HDL-C are endorsed as practical surrogate markers for assessing total atherogenic particle burden, particularly in patients with elevated triglycerides, metabolic syndrome, type 2 diabetes, or obesity, all of which are associated with increased sdLDL concentrations. The gene discussed is APOB; the disease is metabolic syndrome.